Heyholder

This is an amended filing

‹ Activism Filings

Voronoi, Inc. VRN110755 Phase 1/2 Trial Target Raised to 355 Subjects, Australia Amendment Filed

Voronoi, Inc.

AI summary · Not investment advice

Following an Australian protocol update, the VRN110755 Phase 1/2 trial target was changed from around 255 to around 355 subjects in an amendment application.

Commentary

AI commentary · Not investment advice

What happened

Voronoi has applied in Australia for approval to raise the target number of participants in its VRN110755 Phase 1/2 trial from 255 to about 355. The change follows an update to the trial protocol (the trial plan) in Australia. The trial targets advanced non-small cell lung cancer (NSCLC).

In the company's terms

The study combines Phase 1 and Phase 2 in one trial. It can run for up to 6 years, including long-term follow-up. Its registration number is NCT07699328.

What changes for shareholders

The company notified the Australian ethics committee (HREC) of the change application. The materials do not say whether it has been approved or give any later schedule.

Comments

No comments yet

Comments from shareholders will appear here.